Dr. Drubosky is a scientist with a translational research focus on myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). She spends 100% of her time on research. For her doctoral training, Dr. Dubrosky was awarded NIH T32 support under the mentorship of Dr. Christopher R. Cogle.
During her time in training, she discovered that bone marrow endothelial cells protect AML cells from chemotherapy via adhesion molecule interactions. Specifically, Dr. Dubrosky identified the BCAM/VLA5 axis as sufficient to protect AML. She then worked as the Scientific Director of the University of Florida’s precision oncology program, which she have successfully directed and managed since June 2015. She was recently appointed assistant professor to expand her work in functional genomics and computational biology, as well as developing non-invasive methods to monitor MDS and AML patient response to treatment.